Skip to content Skip to footer
Subscribe Now
Amylyx
NEWS

Amylyx Pharmaceuticals Reports the First Participant Dosing in P-III (LUCIDITY) Study Evaluating Avexitide in PBH

SShots:Amylyx has dosed the first participant in its pivotal P-III (LUCIDITY) study of avexitide (90mg) for post-bariatric hypoglycemia (PBH), with recruitment completion expected in 2025 and topline data in the H1’26The P-III (LUCIDITY) study evaluating avexitide (QD) vs PBO in ~75 PBH patients post Roux-en-Y gastric bypass surgery includes a 6wks. screening…
May 1, 2025

Read more

VIEWPOINTS_Richard Stefanacci_2024
VIEWPOINTS

Neurogenerative Disorders Management: Richard Stefanacci of TauRx in an Enlightening Conversation with PharmaShots

Shots: Richard Stefanacci, Chief Medical Officer at TauRx, sheds light on the anti-tau drug Hydronomethylthionine mesylate (HMTM), a potential oral treatment for patients with Alzheimer’s disease and mild cognitive impairment While highlighting the positive results from the LUCIDITY P-III study, Richard speaks about bridging the gap in AD and MCI treatment by lowering the dependence…
March 18, 2024

Read more